B E Elewski

Summary

Publications

  1. Elewski B, Rich P, Pollak R, Pariser D, Watanabe S, Senda H, et al. Efinaconazole 10% solution in the treatment of toenail onychomycosis: Two phase III multicenter, randomized, double-blind studies. J Am Acad Dermatol. 2013;68:600-8 pubmed publisher
    ..A period of 52 weeks may be too brief to evaluate a clinical cure in onychomycosis. Once daily topical efinaconazole appears to be a viable alternative to oral treatment options for onychomycosis. ..
  2. Elewski B, Aly R, Baldwin S, González Soto R, Rich P, Weisfeld M, et al. Efficacy and safety of tavaborole topical solution, 5%, a novel boron-based antifungal agent, for the treatment of toenail onychomycosis: Results from 2 randomized phase-III studies. J Am Acad Dermatol. 2015;73:62-9 pubmed publisher
    ..7%), erythema (1.6%), and dermatitis (1.3%). Duration of follow-up is a limitation. Tavaborole demonstrates a favorable benefit-risk profile in treatment of toenail onychomycosis. ..
  3. Elewski B. Tinea capitis: a current perspective. J Am Acad Dermatol. 2000;42:1-20; quiz 21-4 pubmed
    ..With these changes, prospects for newer therapies with the novel antimycotic agents itraconazole, fluconazole, and terbinafine are reviewed. (J Am Acad Dermatol 2000;42:1-20.)..
  4. Elewski B, Cáceres H, DeLeon L, El Shimy S, Hunter J, Korotkiy N, et al. Terbinafine hydrochloride oral granules versus oral griseofulvin suspension in children with tinea capitis: results of two randomized, investigator-blinded, multicenter, international, controlled trials. J Am Acad Dermatol. 2008;59:41-54 pubmed publisher
    ..Alternative antifungal therapies with shorter/simpler treatment regimens may be important to develop for this indication...

Detail Information

Publications4

  1. Elewski B, Rich P, Pollak R, Pariser D, Watanabe S, Senda H, et al. Efinaconazole 10% solution in the treatment of toenail onychomycosis: Two phase III multicenter, randomized, double-blind studies. J Am Acad Dermatol. 2013;68:600-8 pubmed publisher
    ..A period of 52 weeks may be too brief to evaluate a clinical cure in onychomycosis. Once daily topical efinaconazole appears to be a viable alternative to oral treatment options for onychomycosis. ..
  2. Elewski B, Aly R, Baldwin S, González Soto R, Rich P, Weisfeld M, et al. Efficacy and safety of tavaborole topical solution, 5%, a novel boron-based antifungal agent, for the treatment of toenail onychomycosis: Results from 2 randomized phase-III studies. J Am Acad Dermatol. 2015;73:62-9 pubmed publisher
    ..7%), erythema (1.6%), and dermatitis (1.3%). Duration of follow-up is a limitation. Tavaborole demonstrates a favorable benefit-risk profile in treatment of toenail onychomycosis. ..
  3. Elewski B. Tinea capitis: a current perspective. J Am Acad Dermatol. 2000;42:1-20; quiz 21-4 pubmed
    ..With these changes, prospects for newer therapies with the novel antimycotic agents itraconazole, fluconazole, and terbinafine are reviewed. (J Am Acad Dermatol 2000;42:1-20.)..
  4. Elewski B, Cáceres H, DeLeon L, El Shimy S, Hunter J, Korotkiy N, et al. Terbinafine hydrochloride oral granules versus oral griseofulvin suspension in children with tinea capitis: results of two randomized, investigator-blinded, multicenter, international, controlled trials. J Am Acad Dermatol. 2008;59:41-54 pubmed publisher
    ..Alternative antifungal therapies with shorter/simpler treatment regimens may be important to develop for this indication...